PT - JOURNAL ARTICLE AU - C. Máthé AU - A. Bohács AU - L. Duffek AU - J. Lukácsovits AU - Z.I. Komlosi AU - K. Szondy AU - I. Horváth AU - V. Müller AU - G. Losonczy TI - Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients AID - 10.1183/09031936.00055110 DP - 2011 Apr 01 TA - European Respiratory Journal PG - 888--894 VI - 37 IP - 4 4099 - http://erj.ersjournals.com/content/37/4/888.short 4100 - http://erj.ersjournals.com/content/37/4/888.full SO - Eur Respir J2011 Apr 01; 37 AB - Ageing lung cancer patients may be at increased risk of Cisplatin (Cp) nephrotoxicity, because of comorbidities leading to accelerated ageing of the kidneys. Therefore, the Cp-induced impairement of renal function was compared between no comorbidity (NC) and hypertension plus ischaemic heart disease (CD) patients or others having diabetes mellitus plus ischaemic heart disease (DMIH).In a preliminary study, glomerular filtration rate (GFR) was measured by clearance of technetium 99m-labelled diethylene-thiamine penta-acetate in 38 lung cancer patients with normal serum creatinine concentration ([creat]). Then, the incidence of nephrotoxicity was analysed retrospectively over 1st–4th cycles of Cp treatment among 242 lung cancer patients with initially normal [creat]. GFR was repeatedly estimated using calculated creatinine clearance.Pre-treatment GFR was 57±3 mL·min−1·m−2 in those with normal (n = 15) and 42±2 mL·min−1·m−2 in those with pathologically increased (n = 23) [creat] any time following their 2nd–4th Cp cycle (p<0.05). The retrospective analysis revealed that Cp-induced nephrotoxicity developed in 7.5% of the NC (n = 80), in 20.9% of the CD (n = 110) and in 30.8% of the DMIH (n = 52) subgroups. Within the overall dropout rate from further Cp chemotherapy, nephrotoxicity was responsible in 14% of NC, 38% in CD and 75% in DMIH patients.A major portion of our ageing lung cancer patients suffered from comorbidities leading to reduced renal resistance to Cp nephrotoxicity.